Form 4: Theodore R. Schroeder Acquires Shares and Options in Phathom Pharmaceuticals

Theodore R. Schroeder, a director at Phathom Pharmaceuticals, acquired 21,000 shares of common stock and options to purchase 35,000 shares on April 16, 2025.

Summary

• The document is a Form 4 filing, indicating changes in beneficial ownership of securities.
• Director Theodore R. Schroeder acquired 21,000 shares of Phathom Pharmaceuticals common stock on April 16, 2025.
• These shares were granted as restricted stock units (RSUs) with a vesting schedule.
• Schroeder also acquired options to purchase 35,000 shares of common stock at an exercise price of $4.23.
• These options also have a vesting schedule, contingent on continued service to the Issuer.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard insider transaction. The director's acquisition could be interpreted as a positive signal, but it's not definitively bullish.

Positives

• The acquisition of shares and options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• Shareholders may view the director's acquisition as a positive signal.
• Employees may see it as a sign of confidence in the company's future.

Key Dates

Keywords

Form 4, beneficial ownership, Phathom Pharmaceuticals, stock options, restricted stock units, director, Schroeder, PHAT